Form 10-D SCE Recovery Funding For: Nov 30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-D
ASSET-BACKED ISSUER DISTRIBUTION REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the semi-annual distribution period from:
6/01/2023 to 11/30/2023 for the 2023-A Bonds
| Commission |
Registrant; State of Incorporation; Address; and Telephone Number |
IRS Employer | ||
| 333-249674-01 | SCE Recovery Funding LLC
Delaware 2244 Walnut Grove Ave, Rosemead, CA 91770 (P.O. Box 5407) (626) 302-7255 |
85-3002154 | ||
| 1-2313 | SOUTHERN CALIFORNIA EDISON COMPANY (Depositor and Sponsor)
California 2244 Walnut Grove Ave, Rosemead, CA 91770 (P.O. Box 800) (626) 302-1212 |
95-1240335 | ||
| Registered/reporting pursuant to (check one) |
Name of exchange (if Section 12(b)) |
|||||||||
| Title of class |
Section 12(b) | Section 12(g) | Section 15(d) | |||||||
| Senior Secured Recovery Bonds, Series 2023-A |
☐ | ☐ | ☒ | |||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
PART 1 - DISTRIBUTION INFORMATION
Item 1. Distribution and Pool Performance Information.
The response to Item 1 is set forth in part herein and in part in Exhibit 99.1.
The record date for distributions described in Exhibit 99.1 is December 14, 2023.
Introductory and explanatory information regarding the material terms, parties, and distributions described in Exhibit 99.1 is included in the Prospectus dated April 19, 2023, of SCE Recovery Funding LLC (Issuing Entity) relating to the Senior Secured Bonds, Series 2023-A (the Bonds) filed with the Securities and Exchange Commission pursuant to Rule 424(b)(1) of the Securities Act of 1933 on April 21, 2023.
As indicated in Exhibit 99.1, all required interest and scheduled principal payments on the Bonds have been made with respect to the December 15, 2023 distribution date.
The following Items have been omitted pursuant to General Instruction C of Form 10-D:
| | Item 1 A. Asset-Level Information. |
| | Item 1 B. Asset Representations Reviewer and Investor Communication. |
PART II - OTHER INFORMATION
Item 2. Legal Proceedings.
None.
Item 3. Sale of Securities and Use of Proceeds.
None.
The following Items have been omitted pursuant to General Instruction C of Form 10-D:
| | Item 4. Defaults Upon Senior Securities. |
| | Item 5. Submission of Matters to a Vote of Security Holders. |
| | Item 6. Significant Obligors of Pool Assets. |
| | Item 7. Change in Sponsor Interest in the Securities. |
| | Item 8. Significant Enhancement Provider Information. |
Item 9. Other Information.
None.
Item 10. Exhibits
| (a) | The Following is a list of documents filed as part of this Report on Form 10-D. |
2
Exhibits filed here within are designated by an asterisk (*). All exhibits not so designated are incorporated by reference to a prior filing, as indicated.
| (b) | The exhibits required to be filed by the Registrant pursuant to Item 601 of Regulation S-K (17 CFR 229 601) as listed above. |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: December 29, 2023 | SCE Recovery Funding LLC (Issuing Entity) | |||
| By: SCE Recovery Funding LLC, as Servicer | ||||
| /s/ Natalia Woodward | ||||
| Natalia Woodward | ||||
| Vice President & Treasurer | ||||
4
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cryptocurrency News: Reported Drift Hack Transfers Hit $61.56M as Remittix Earn Readies Morpho, Fluid and Maple Finance Pools
- Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
- Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share